Progress in the Synthesis of DN29 for Cancer Drug Development

Grace Gibson
Dr. Justine R. Olson, Faculty Mentor

APOBEC3 is a highly-expressed protein common in late-stage and particularly stubborn cancers. DN29 has been discovered computationally by Dr. Bill Miller at TSU to have a great binding affinity to this protein, and could be used as part of a cancer treatment. The synthesis of this molecule requires three steps, the first of which uses a Friedel-Crafts addition type reaction between 1-methylindole and 5-methylisatin. Attempts of this synthesis and results will be discussed.

Keywords: Chemistry, Friedel-Crafts, Cancer, Drug Development

Topic(s):Chemistry

Presentation Type: Oral Presentation

Session: 106-2
Location: MG 2001
Time: 9:30

Add to Custom Schedule